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Abstract
α-Isopropylmalate synthase (α-IPMS) catalyses the first committed step in leucine
biosynthesis in bacteria, including Neisseria meningitidis and Mycobacterium tuber-
culosis. It catalyses the condensation of α-ketoisovalerate (α-KIV) and acetyl coen-
zyme A (AcCoA) to form α-isopropylmalate (α-IPM). Like many key enzymes in
biosynthesis, α-IPMS is inhibited by the end-product of the biosynthetic pathway,
in this case leucine. α-IPMS is homodimeric, with monomers consisting of a (β/α)8-
barrel catalytic domain, two subdomains and a C-terminal regulatory domain, re-
sponsible for binding leucine and providing feedback inhibition for leucine biosyn-
thesis.
The exact mechanism of feedback inhibition in this enzyme is unknown, despite
the elucidation of crystal structures with and without leucine bound. This thesis
explores the nature of allosteric regulation in α-IPMS, including the effects of the
regulatory domain and the importance of structural asymmetry on catalytic activ-
ity.
Chapter 2 details the characterisation of wild-type α-IPMS from N. meningitidis
(NmeIPMS). This protein was successfully cloned, expressed and purified by metal-
affinity and size-exclusion chromatography. NmeIPMS has similar characteristics to
previously characterised α-IPMSs, being a dimer and demonstrating substrate bind-
ing affinities in the micromolar range. This enzyme has a turnover number of 13 s−1
and is sensitive to mixed, non-competitive inhibition by the amino acid leucine.
Small angle X-ray scattering experiments reveal that the solution-phase structure
of this protein is likely similar to existing crystal structures of other α-IPMSs.
In Chapter 3, substitutions of residues potentially involved in the binding and trans-
mission of the leucine regulatory mechanism are described. Most of these amino acid
substituted variants reduce enzyme sensitivity to leucine, and one variant is almost
entirely insensitive to this inhibitor. Another of these variants demonstrates an un-
expected decrease in substrate affinity, despite the substituted residue being located
iii
far from the active site.
The independence of α-IPMS domains is investigated in Chapter 4. The cata-
lytic domains were isolated from NmeIPMS and the α-IPMS from M. tuberculosis
(MtuIPMS), and found to be unable to catalyse the condensation of substrates,
despite maintaining the wild-type structural fold. Complementation studies with
Escherichia coli cells lacking the gene for α-IPMS show that the truncated variants
are unable to rescue growth in these cells. Binding of α-KIV in the truncated Nme-
IPMS variant is much stronger than in the wild-type, and this may be the reason for
lack of competent catalysis. A crystal structure was solved for the truncated vari-
ant of NmeIPMS and indicates that the regulatory domain is required for proper
positioning of large regions of the protein. Two isolated regulatory domains from
NmeIPMS were cloned, but with limited success in characterisation.
Finally, Chapter 5 describes substitutions made in MtuIPMS to affect relative do-
main orientations within the protein. Dimer asymmetry is investigated by substi-
tuting residues at the domain interfaces. These substitutions did have some effect
on catalysis and inhibition, but did not show any change in average solution-phase
structure.
These results are drawn together in the greater context of allostery in general in
Chapter 6, along with ideas for future research in this field. This chapter reviews the
insights gained into protein structure from this thesis, particularly the importance
of residues at protein domain interfaces. The asymmetry in the α-IPMS structure
is discussed, along with small-molecule binding regulatory domains.
iv
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Introduction
1.1 Branched-chain amino acid biosynthesis
Antibiotics, by their nature, exploit the differences between pathogenic and mam-
malian cells. The ability to target cells of a particular organism or a particular class
of organisms is what distinguishes antibiotics from poisons. Studying key biosyn-
thetic pathways that are critical for life in bacteria, but are absent from mammals,
allows for the development of targeted treatments for pathogenic infections that do
not harm the infected host.
Among these key biosynthetic pathways are those responsible for production of
amino acids — the building blocks of proteins and, by extension, cells. Organisms
may generate these building blocks in one of two ways, either by the breakdown of
ingested protein or by synthesis within the cell. Humans obtain ten of the twenty
standard amino acids from diet; these ten are classified as the “essential” amino
acids.1 All three branched-chain amino acids — valine, leucine and isoleucine — are
essential to humans but are synthesised in fungi,2 plants3 and bacteria.4,5
Several studies have shown that genetic knockouts of enzymes in the branched-
chain amino acid biosynthetic pathway lead to auxotrophic mutants, unable to
grow without amino acid supplementation (see Section 1.1.3). Thus, disruption
of this pathway could be a potential treatment for pathogenic infection, making
the branched-chain amino acid biosynthetic pathway a viable target for antibiotic
design.
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1.1.1 Valine and isoleucine biosynthesis
Pyruvate is the starting compound for the committed biosynthetic pathways of all
three branched-chain amino acids, although the biosynthesis of isoleucine is also
dependent on a threonine precursor in many organisms.6 Valine and isoleucine are
synthesised by near identical methods and share enzymes for many steps in their
pathways (Figure 1.1). The dedicated leucine pathway branches off from α-keto-
isovalerate (α-KIV), the immediate precursor to valine. Each of the first commit-
ted steps in these pathways are inhibited by one or more branched-chain amino
acids.
The the first step towards isoleucine biosynthesis is the formation of α-ketobutyrate
(α-KB) from threonine by the enzyme threonine deaminase (TD). TD is inhibited
allosterically by isoleucine, and this inhibition can be reversed by valine.7 An al-
ternative, threonine-independent route to α-KB occurs in some bacteria via the
citramalate pathway (shown in grey in Figure 1.1).8 This pathway starts with the
condensation of pyruvate and acetyl coenzyme A (AcCoA) by citramalate synthase
(CMS) to form citramalate. Like TD, this enzyme is inhibited by isoleucine.9 From
citramalate a further two enzymes are required to form α-KB.
The next enzyme in branched-chain amino acid synthesis is acetohydroxyacid syn-
thase (AHAS), which catalyses the reaction between α-KB and pyruvate to form
α-aceto-α-hydroxybutyrate. This same enzyme can also catalyse the first committed
step in valine biosynthesis, taking a second pyruvate molecule as a substrate in place
of α-KB to form α-acetolactate.10 AHAS is comprised of separate catalytic and reg-
ulatory subunits,11,12 where association of the regulatory subunit is required for full
activity in the catalytic site.13 This enzyme is regulated by valine, isoleucine and
leucine, often with a preference for valine and some synergy between inhibitors.6,14
For example, AHAS from Arabidopsis thaliana is inhibited by each of isoleucine,
valine and leucine, and also synergistically by combination of leucine with either of
the other two branched-chain amino acids.15
From AHAS onward the biosynthetic pathways to isoleucine and valine run in paral-
lel. First, α-acetolactate and α-aceto-α-hydroxybutyrate are isomerised and reduced
by acetohydroxyacid isomeroreductase (AHAIR). The products of these reactions are
then dehydrated by dihydroxyacid dehydratase (DHAD) and finally transaminated
by branched-chain aminotransferase (BCAT) to form the amino acids. Although
AHAS is the main point of regulation in the shared pathway, both AHAIR and
DHAD may also be inhibited by valine and leucine in some organisms.16
2
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Figure 1.1: The branched-chain amino acid biosynthetic pathway. TD — threonine deam-
inase; CMS — citramalate synthase; AHAS — acetohydroxyacid synthase; AHAIR — aceto-
hydroxyacid isomeroreductase; DHAD — dihydroxyacid dehydratase; BCAT — branched-chain
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1.1.2 The leucine biosynthetic pathway
The last step in valine biosynthesis is the transamination of α-KIV by BCAT, but
α-KIV is also the first substrate of the predominant bacterial leucine biosynthetic
pathway.17 This pathway is shown in Figure 1.2, with details of the chemistry in-
volved.
The first committed step in leucine biosynthesis is the condensation of α-KIV and
AcCoA to form α-isopropylmalate (α-IPM). This reaction is catalysed by α-iso-
propylmalate synthase (α-IPMS) and inhibited by leucine. From α-IPM, a hydroxyl
group is transferred between adjacent carbons to form β-isopropylmalate, via an iso-
propylmaleate intermediate. This dehydration and rehydration is catalysed by α-iso-
propylmalate isomerase (IPMI). β-Isopropylmalate is then oxidised to α-isopropyl-
β-oxosuccinate and decarboxylated to form α-ketoisocaproate (α-KIC), both steps
catalysed by β-isopropylmalate dehydrogenase (IPMD). As for valine and isoleucine
biosynthesis, the last step in the leucine pathway is transamination by BCAT to
form the amino acid.
Some of the enzymes in leucine biosynthesis are also used in the threonine-independent
formation of α-KB. The last three steps in this formation of α-KB from pyruvate are
the dehydration of citramalate to form α-methylmaleate, followed by rehydration to
β-methylmalate and oxidative decarboxylation to give the α-keto acid.8,18,19 These
reactions parallel those seen in the formation of α-KIC from α-IPM, and the same
promiscuous enzymes (IPMI and IPMD) are used. The first reaction in this path-
way is the condensation of pyruvate and AcCoA, which is catalysed by CMS and is
analogous to the α-KIV/AcCoA condensation reaction of α-IPMS.
4
Introduction
valine 
from pyruvate 
!-ketoisovalerate 
O
O-
O
leucine 
!-ketoisocaproate 
O
O-
O
"-isopropylmalate 
O
O-
O O-
OH
!-isopropylmalate 
!-IPMS (-) 
IPMI 
IPMD 
BCAT 
AcCoA
CoA
H2O
?-ketoglutarate
glutamate
NAD+
H+
NADH
CO2
O
NH3+
O-
O O-
O
O-
OH
Figure 1.2: The leucine biosynthetic pathway. α-IPMS — α-isopropylmalate synthase;
IPMI — α-isopropylmalate isomerase; IPMD — β-isopropylmalate dehydrogenase; BCAT —
branched-chain aminotransferase. The symbol (-) indicates point of regulation.
5
Chapter 1
1.1.3 Branched-chain amino acid biosynthesis as a drug
target
Evidence from genetic mutation and inhibitor assays suggests that the branched-
chain amino acid biosynthetic pathway is a viable drug target. Many of the enzymes
in this pathway have proven critical to cell viability, with deletion or mutation of
corresponding genes resulting in auxotrophy for one or more branched-chain amino
acids (Table 1.1).
Enzyme (gene) Auxotrophy Species
TD (ilvA) Ile Salmonella typhimurium,4 Lemna minor 3
AHAS (ilvB) Val, Ile, Leu Corynebacterium glutamicum 20 Mycobacterium
tuberculosis 5
BCAT (ilvE ) Val, Ile, Leu Corynebacterium glutamicum,21 Salmonella typh-
imurium 4
α-IPMS (leuA) Leu Corynebacterium glutamicum,22 Escherichia coli,23
Lactococcus lactis,24 Methanococcus maripaludis,25
Salmonella typhimurium,2 Neurospora crassa 2
IPMI (leuC/D) Leu Mycobacterium bovis BCG,26,27 Mycobacterium
tuberculosis 28
IPMD (leuB) Leu Bifidobacterium globosum,29 Escherichia coli,23
Lactococcus lactis,24 Pseudomonas aeruginosa 30
Table 1.1: Examples of branched-chain amino acid auxotrophy, detailing genes affected,
auxotrophy conferred and the species in which this was observed
Many enzymes in the branched-chain amino acid pathway are also known to be tar-
gets for herbicides. AHAS is a common target for commercially available compounds
such as sulfonylaminocarbonyltriazolinones, triazolopyrimidines, pyrimidinylsalicylic
acids, sulfonylureas and imidazolinones,14 whereas AHAIR can be inhibited by a
variety of potentially herbicidal compounds, including cyclopropane-1,1-dicarboxyl-
ate31 and thiadiazoles.32 Other inhibitors have also been demonstrated to affect TD,
IPMI and IPMD.14,33–35
Despite its critical role in all three branched-chain amino acid pathways, BCAT is
not an attractive inhibitor target due to its presence in mammals, where it is used
in branched-chain amino acid catabolism.
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Inhibition of leucine biosynthesis in the treatment ofM. tuberculosis
The leucine biosynthetic pathway has been the target for development of several new
vaccines against M. tuberculosis . Currently, vaccines are undertaken with Mycobac-
terium bovis Bacillus Calmette-Gue´rin (BCG), an avirulent strain of M. bovis , but
this has disadvantages in that it may have pathogenic effects on individuals with
compromised immune systems, and that inoculation with this strain gives false-
positives in the tuberculin test for M. tuberculosis infection.36
Deletion of the gene ilvB1 in M. tuberculosis , which encodes the major catalytic
subunit of AHAS, has been shown to reduce cell growth of this pathogen in mice,
but not affect cell viability of the bacteria in either mice or macrophages.5 The
persistence of these mutant M. tuberculosis cells within the host, coupled with de-
fective growth, shows potential for vaccine development. Similarly, inactivation of
gene ilvE in M. tuberculosis , encoding DHAD, reduces cell growth in mice and in
culture.37
Several studies have found that the removal of IPMI activity from M. bovis BCG
(through inactivation of the leuD gene) results in mutant cells unable to grow in
mice or macrophages,27 and cleared from the lungs and spleen in mice within seven
weeks.26 This strain protects guinea pigs from infection with M. bovis or M. tuber-
culosis , and does not give false-positive results for the tuberculin skin test in these
animals.36
A double-knockout strain of M. bovis BCG lacking the leuD and panCD genes
also protects guinea pigs from infection, with no adverse side-effects seen in simian
immunodeficiency virus-infected Rhesus macaques.38 PanCD is involved in the bio-
synthesis of pantothenate.
In addition to aiding the development of new vaccines, the branched-chain amino
acid biosynthetic pathway has shown some promise as a target of antibiotic agents
against M. tuberculosis . The AHAS inhibitor sulfometuron methyl is more effect-
ive than frontline anti-tuberculosis drugs against antibiotic-resistant M. tuberculosis
strain T13704, lowering pathogenic cell numbers in the lungs, but not the spleen, of
mice.39 The AHAIR inhibitor N -isopropyloxalyl hydroxamate has also shown some
antibiotic effects against antibiotic resistantM. tuberculosis . Both of these inhibitors
were initially developed as herbicides, so it is possible that with further development
they could lead to effective antibiotics.
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1.2 α-Isopropylmalate synthase
α-IPMS (EC 2.3.3.13) catalyses the first committed step in leucine biosynthesis. It is
the product of the gene leuA (leu4 in Saccharomyces cerevisiae), and belongs to the
Claisen-condensing family of enzymes, which catalyse the condensation of AcCoA
with an α-keto acid. Other members of this enzyme family include malate synthase,
methylthioalkylmalate synthase, re- and si -citrate synthases, homocitrate synthase
and citramalate synthase. Many of these enzymes require a divalent metal ion for
polarisation of the α-keto substrate, with the exception of si -citrate synthase, which
uses a pair of histidine residues for this purpose.40
α-IPMSs from a range of organisms have been studied, including those from plants
(notably A. thaliana 41), fungi (N. crassa,42 S. cerevisiae 43) and bacteria (M. tuber-
culosis ,44–52S. typhimurium,53 Corynebacterium glutamicum 22). A sequence align-
ment of some of the characterised α-IPMSs can be found in Appendix A. This
alignment also indicates the major domains and secondary structure elements of
the protein, as evidenced from crystal structures of α-IPMS from M. tuberculosis
(MtuIPMS).51,54
The most in-depth α-IPMS studies have been carried out on MtuIPMS, due to the
potential for drug development against this pathogen. The gene for MtuIPMS is
unusual amongst α-IPMSs in that it demonstrates sequence polymorphism, with
different strains of M. tuberculosis containing different numbers of copies of a 57
base-pair tandem repeat. The number of copies of the repeat can be between two
and 21, with two copies being the most common;55 the deletion of this sequence
does not affect enzyme activity or expression.56 This variable-number tandem repeat
(VNTR) is represented twice (residues 575–612) in the α-IPMS from M. tuberculosis
strain H37Ra, which is the MtuIPMS homologue described in this thesis.
1.2.1 Enzyme function
α-IPMS catalyses the condensation of α-KIV and AcCoA to form α-IPM (Figure 1.3).
The enzyme provides maximum catalysis at slightly basic pH, with broad activity
peaks around pH8.5 in bacteria41,53,57 and between pH7.0 and 8.5 in fungi.42,58
α-KIV and AcCoA have Km values in the range of tens to hundreds of micromolar,
with turnover numbers in single digits per second (Table 1.2). Studies into the effect
of the VNTR inMtuIPMS suggest that high numbers of repeats increase the binding
affinity of the enzyme for both substrates while decreasing turnover number.59 Mtu-
8
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IPMS is also able to catalyse the α-KIV-independent hydrolysis of AcCoA with a
Km of 160 ￿M and a turnover number of 0.03 s−1. The product CoA has been shown
to inactivate α-IPMSs from S. typhimurium and S. cerevisiae.60,61 Such inactivation
is also seen in S. cerevisiae homocitrate synthase, though not in S. cerevisiae citrate
synthase.62
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Figure 1.3: Reaction catalysed by α-IPMS
Km (￿M)
Organism α-KIV AcCoA kcat (s−1)
Mycobacterium tuberculosis 46 12 136 3.5
Salmonella typhimurium 53 60 200
Saccharomyces cerevisiae 58 16 9
Neurospora crassa 42 25
Arabidopsis thaliana isozyme 141 304 45 2.4
Arabidopsis thaliana isozyme 241 279 16 2.3
Table 1.2: Kinetic data of characterised α-IPMSs. Some data not determined for some
orthologues.
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Metal dependence
α-IPMS requires a divalent metal ion for activity in all organisms studied. Mg2+ usu-
ally gives rise to highest catalytic activity in the enzyme, followed by Mn2+.41,43,47
Other divalent metal ions may activate or inhibit: Co2+ is activating for M. tubercu-
losis and S. cerevisiae α-IPMSs,43,47 but has no effect on A. thaliana α-IPMS;41 Ni2+
and Ca2+ are activating forMtuIPMS but inhibitory for A. thaliana α-IPMS.41,47
These differences in metal dependency could be due to enzyme preference, but may
also be due to methods of analysis. For instance, Zn2+ and Cd2+ were shown to be
inhibitory forMtuIPMS,47 but later studies suggest that this was due to interference
with the assay reporter compound.63
α-IPMSs from S. cerevisiae, N. crassa and M. tuberculosis show a requirement for
monovalent cations, with a clear preference for K+, although Na+ and NH4+ are also
activating.42,47,58 These cations have no effect on substrate Km values for MtuIPMS,
but do affect activation by Mg2+. It is thought that monovalent cations may act to
recruit divalent metal ions to the active site.47
Alternate substrates
In addition to α-KIV (the natural α-keto acid substrate) many α-IPMSs are also able
to catalyse the condensation of AcCoA with pyruvate, α-KB or α-ketovalerate (Table
1.3). Many of these enzymes are inhibited by α-KIC, including those from Alcali-
genes eutrophus ,64 S. typhimurium,53 and S. cerevisiae.58 α-KIC is the penultimate
compound in the leucine biosynthetic pathway.
The two isozymes of α-IPMS from A. thaliana seem to have a greater tolerance for
chain length variation than the bacterial and fungal enzymes, and can utilise glyoxal-
ate, α-keto-β-methylvalerate, α-KIC and α-ketocaproate as weak substrates.41
α-Hydroxyisovalerate has been shown to inhibit MtuIPMS, confirming the import-
ance of the α-keto group in the α-keto acid substrate.46 α-IPMS has a very strict
tolerance for AcCoA, and generally will not accept other acyl-CoA analogues as
alternate substrates. Some slight condensation activity has been observed with
propionyl-CoA, however the majority of free CoA released by the enzyme in the
presence of this substrate is due to α-KIV-independent hydrolysis. This is also true
of the longer acyl-CoA analogue crotonyl-CoA.46
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Compound Structure Activity [see footnote]
Glyoxalate
O
O-
O
Weak substrate [f]
No activity [b]
Pyruvate
O
O-
O
Substrate [a–f]
α-Ketobutyrate
O
O-
O
Substrate [a–f]
α-Ketoisovalerate
O
O-
O
Natural substrate
(S)-α-Hydroxyisovalerate O
-
O
OH
Inhibitor [b]
α-Ketovalerate
O
O-
O
Substrate [a–c,f]
Inhibitor [f]
α-Keto-β-methylvalerate
O
O-
O
Weak substrate [f]
No activity [b]
α-Ketoisocaproate
O
O-
O
Weak substrate [f]
Inhibitor [a–d,f]
α-Ketocaproate
O
O-
O
Weak substrate [f]
α-IPMSs from:
(a) Alcaligenes eutrophus 64
(b) Mycobacterium tuberculosis 46
(c) Salmonella typhimurium 53
(d) Neurospora crassa 42
(e) Saccharomyces cerevisiae 58
(f) Arabidopsis thaliana 41
Table 1.3: α-Keto acid specificity of α-IPMS
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Reaction mechanism
The divalent metal ion in α-IPMS is proposed to coordinate the carbonyl groups of
α-KIV and to polarise the α-keto group during catalysis, while it is thought that
a monovalent cation may introduce structural changes to bind the divalent metal
ion and the substrate more tightly.47 However, not all variants of α-IPMS require
monovalent cations, and hypotheses about any possible function and location are
entirely conjecture at this point as there is no sign of such a cation in the solved
crystal structures.51
The α-IPMS enzymatic reaction proceeds through enolisation of AcCoA, followed by
condensation to form α-isopropylmalyl-CoA (Figure 1.4). The CoA moiety is then
hydrolysed to give α-IPM. This reaction is proposed to involve one acidic and two
basic amino acids within the α-IPMS active site.46
CH3
O CoA
O
O-
O
Mg2+
A
H
B1
H2C
O CoA
O
O-
O
Mg2+
A
H
B1H
H2C
O CoA
HO
O-
O
Mg2+
HB1
H2O
B2
H2C
-O CoA
HO
O-
O
Mg2+
OH
B2
H
H2C
-O CoA
HO
O-
O
Mg2+
HO
B2H
-CoA
HO
O-
O
Mg2+
OHO
Figure 1.4: Detailed mechanism of α-IPMS reaction, as proposed by de Carvalho et al.46 A,
B1 and B2 are proposed acidic and basic residues in the enzyme active site.
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Feedback inhibition by leucine
Like many enzymes which catalyse the first committed step in a biosynthetic path-
way, α-IPMS demonstrates feedback inhibition by the pathway end-product, in this
case leucine.42
Leucine has similar affinity for both the free and substrate-bound forms ofMtuIPMS,
with a Ki of 8 ± 1 ￿M and a K ￿i of 22 ± 2 ￿M with respect to α-KIV.45 Inhibition is
mixed and slow-onset in this enzyme, indicating a possible isomerisation event from
the Enz·Leu complex to a more tightly bound Enz*·Leu complex. This complex has
an inhibition constant (Ki*) of 3.6 ± 2.2 ￿M, calculated from the linear, steady-state
phase of leucine inhibition kinetics, as opposed to the initial velocity rates used to
find the Ki and K ￿i .
Inhibition in many α-IPMSs is pH dependent, with weaker inhibition evident at
higher pH values.42,53 The number of VNTRs is also important in MtuIPMS regula-
tion, as no inhibition is observed in MtuIPMS isozymes with large numbers of these
repeats.59
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1.2.2 Overall structure
The only reported full-length α-IPMS crystal structures so far determined are from
M. tuberculosis .51 These structures show α-KIV, citrate, α-KIC or bromopyruvate
bound at the active site (Protein Data Bank [PDB] codes 1SR9, 3HQ1, 3HPS and
3HPZ) or leucine bound in the regulatory domain (PDB code 3FIG). No unliganded
or AcCoA-bound full-length structures have yet been solved.
MtuIPMS is a 70 kDa monomer that forms a dimer in solution and in the crystal
structure (Figure 1.5).46,51 Other organisms have been shown to possess trimeric or
tetrameric α-IPMSs.41,42,65
90° 
Figure 1.5: Crystal structure of α-IPMS from M. tuberculosis (PDB code 1SR9). Monomers
are shown in different colours. α-KIV (yellow) and Zn2+ (black) are shown in the active sites.
Leucine (orange) has been overlaid from structure 3FIG (leucine-bound MtuIPMS).
Each monomer ofMtuIPMS is composed of two domains and two subdomains, separ-
ated by a flexible linker (Figure 1.6). The largest protein domain is the N-terminal,
catalytic (β/α)8-barrel. This domain contains the active site, with substrate and
divalent metal-ion binding sites at the C-terminal end of the barrel. Next is the
small subdomain I, formed from two short β-strands and an α-helix, which crosses
over in the dimer to sit over the active site of the adjacent monomer, and contrib-
utes two residues into the potential AcCoA binding cavity. The 9-residue flexible
linker region is disordered in the crystal structures, and connects subdomain I to
subdomain II. This second subdomain comprises three α-helices and is intimately
associated with the C-terminal regulatory domain, itself composed of two (βββα)2
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units arranged so as to sandwich the α-helices between the β-sheets. The regulatory
domain contains two leucine binding sites at its dimeric interface and two VNTRs
that are undefined in the crystal structures.
(a) Monomer A (b) Monomer B
Figure 1.6: Domains in MtuIPMS, shown in both conformations observed in the asymmetric
dimer of crystal structure 1SR9. Catalytic domain in green, subdomain I in blue, subdomain II
in pink and the regulatory domain in purple. The disordered 9-residue linker region connects
the two subdomains.
Asymmetry within the protein dimer is evident in all full-length crystal structures
of MtuIPMS. This asymmetry is due to different relative positions in each monomer
of the C-terminal domains (the regulatory domain and subdomain II) from the N-
terminal domains (subdomain I and the catalytic domain), as shown in Figure 1.6.
The structural difference appears to be mediated by the flexibility of the undefined
linker region.
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1.2.3 Active siteα-KIV and metal ions
A metal ion is essential for catalysis in α-IPMS, as it coordinates and polarises the
carbonyl groups of α-KIV during the reaction. Crystal structures have elucidated
the binding of the divalent metal ion and the substrate α-KIV (Figure 1.7), however
the position of the monovalent cation required for activity in some α-IPMSs remains
undefined.
Figure 1.7: Stereo diagram of α-KIV binding in MtuIPMS structure 1SR9. α-KIV is shown
in yellow, Zn2+ in black and water in red.
In MtuIPMS crystal structure 1SR9, a Zn2+ ion coordinates with two carbonyl
groups of α-KIV, a water molecule and the side chains of Asp81, His285 and His287.
α-KIV forms two other hydrogen bonds with Arg80 and Thr254. All of these metal-
and substrate-binding residues are highly conserved in α-IPMS enzymes, except
His287 which is a glutamine in both A. thaliana isozymes. The methyl groups
of α-KIV are surrounded by Leu143, His167, Ser216, Asn250 and Pro252, which
are also very well conserved and dictate the α-keto acid specificity of the enzyme.
The equivalent histidine, serine and asparagine have been substituted for shorter
amino acids (alanine or glycine) in E. coli α-IPMS to create a variant with increased
promiscuity towards α-keto acids.66 Increased promiscuity was also seen in a double
substitution of the equivalent serine and proline (both to glycine) in A. thaliana
α-IPMS.67
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Binding of AcCoA
No crystal structure of α-IPMS has been solved with AcCoA bound, however such
a structure does exist for the related enzyme CMS from Leptospira interrogans .68
This enzyme catalyses the condensation of AcCoA and pyruvate as the first step in
the threonine-independent synthesis of isoleucine, and is inhibited by isoleucine in
a similar manner to leucine inhibition of α-IPMS.
The active site of CMS is very similar to that of MtuIPMS (Figure 1.8), with a
Zn2+ ion coordinating with two histidine residues, an aspartate, a water molecule
and two oxygens of the α-keto acid substrate (in this case pyruvate). Pyruvate forms
hydrogen bonds with a threonine and an arginine, just as α-KIV does in MtuIPMS.
A molecule of AcCoA sits in the cavity adjacent to pyruvate, where the acetyl oxygen
forms a hydrogen bond to Arg16 while the methyl carbon lies between Glu146 and
pyruvate. It is proposed that Glu146 acts as a catalytic base to enolise AcCoA in
CMS, while Arg16 stabilises this enol form.68 These two residues are well conserved
and are equivalent to Glu218 and Arg80 in α-IPMS.
Figure 1.8: Active site of CMS (PDB code 3BLI — blue) overlaid with that of MtuIPMS
(1SR9 — green). AcCoA is shown in pink, pyruvate in purple and α-KIV in yellow. Zn2+ is
shown in black (CMS) and grey (MtuIPMS). Key residues are labelled for CMS (black) and
α-IPMS (grey), and bonding in CMS is indicated.
Modelling studies with AcCoA in MtuIPMS have indicated that the acetyl moiety
binds in much the same way as in CMS. The acetyl oxygen forms a hydrogen bond
with Arg80, while the methyl carbon sits between invariant residue E218, α-KIV and
the subdomain I residue His379￿ (Figure 1.9),51 where the prime symbol (￿) denotes
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residues that cross over from the adjacent monomer. The methyl carbon and the
carbonyl oxygen of the modelled AcCoA displace water molecules observed in the
crystal structure.
Figure 1.9: Modelled AcCoA binding in MtuIPMS. Each monomer is shown in a different
colour. AcCoA is shown in pink, α-KIV in yellow and Zn2+ in black.
Two basic residues and one acidic residue are necessary for catalysis in MtuIPMS,46
but the nature of these residues is unknown due to the number of conserved ionisable
active site residues, including Arg80, Asp81, Glu218, Glu317, Arg318, His379￿ and
Tyr410￿.
The modelled structure suggests that enolisation of the acetyl carbon could be
achieved by Glu218 or His379￿, while Arg80 acts to stabilise the acyl carbonyl group
during enolisation. Analogy with CMS would suggest that Glu218 is the catalytic
base in MtuIPMS, and substitution of Glu218 with alanine reduces the enzyme kcat
40-fold.48 Similar substitution of His379￿ for alanine has a far less pronounced effect
on catalysis, however the fact that neither of these substitutions completely abolish
activity in MtuIPMS suggests either that there is some redundancy in the residue
responsible for enolisation, or that this catalysis is promoted by one of the other
highly conserved residues in the AcCoA binding pocket such as Glu317, Arg318 or
Tyr410￿. Interestingly, the E218A substitution also increases the leucine affinity of
the free enzyme 10-fold, suggesting that the substitution of this residue may affect
the distant leucine-binding site. Further substitutions of Arg80, Arg318 and Tyr410￿
to alanine in MtuIPMS have resulted in loss of catalytic activity.54
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1.2.4 Structural elements of regulation
The leucine binding site
Leucine binding in MtuIPMS has been elucidated by the crystal structure 3FIG.51
Two leucines bind at the dimer regulatory-domain interface, as shown in Figure
1.10. The carboxyl group of leucine forms hydrogen bonds with the main-chain
functional groups of Ala536 from one monomer and Ile627￿ from the other. The
leucine amino group forms bonds with the side-chain carbonyl of Asn532 and the
main-chain carbonyl of Ala565￿. The hydrophobic end of the inhibitor is surrounded
by Val551, Tyr554, and Leu535.
Isothermal titration calorimetry (ITC) shows that leucine binds to MtuIPMS with
a KD of 3.0 ± 0.6 ￿M,48 comparing favourably with the Ki* of 3.6 ± 2.2 ￿M found
for steady-state inhibition kinetics.45
Figure 1.10: Stereo diagram of leucine binding in MtuIPMS from crystal structure 3FIG.51
Each monomer is shown in a different colour, leucine is shown in orange.
There are several conserved residues in the regulatory domain, most notably a G-
x-G-P-[VIL] motif (residues 531–535 in MtuIPMS) that forms a loop in the leucine
binding site. The variable residue in this motif is an asparagine inMtuIPMS and con-
tributes a hydrogen bond to the leucine amino group, while the leucine residue forms
part of the hydrophobic binding pocket around the inhibitor. Substitution of either
of the glycines in this motif results in leucine insensitivity in S. cerevisiae α-IPMS.69
Similar results are observed for the motif proline in E. coli α-IPMS.70
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Most hydrogen bonds to leucine in MtuIPMS occur through protein main-chain
functional groups, from residues that are for the most part poorly conserved. The
exception to this is Ile627, which is conserved as isoleucine or valine, and forms part
of the hydrophobic pocket in addition to coordinating with the leucine carboxyl
moiety through its main-chain amino group. Other conserved residues in the hydro-
phobic pocket are an invariant tyrosine (Tyr554 in MtuIPMS) and two conserved
branched-chain amino acids (Val551 and Val571 in MtuIPMS).
Conserved residues in the wider MtuIPMS regulatory domain include Ala541 and
Ala634, both in the domain α-helices, and Ser631, which forms a stabilising hydrogen
bond to Ile627 in the inhibitor binding pocket. Two invariant glycines (Gly620 and
Gly622) are found at the interface of the regulatory domain with subdomain II,
while a third (Gly562) is located in a flexible loop covering the binding site.
The leucine binding site flexible loop is formed by residues Met559–Gln566, and has
recently been found to be the reason for the slow-onset nature of leucine inhibition
observed inMtuIPMS.44 A slight change in position of the loop is the only structural
change between leucine-bound and unbound crystal structures, and alanine-scanning
mutagenesis suggests that the two-stage inhibition kinetics in this enzyme can be
attributed to closing of these residues over the inhibitor binding site. Deletion of a
residue in this loop has conferred leucine resistance in S. cerevisiae α-IPMS, as does
substitution of an alanine (Ala552 in S. cerevisiae α-IPMS) for a polar threonine.69
This alanine is equivalent to Ala568 in MtuIPMS.
Figure 1.11: Loop closing in the leucine binding site of MtuIPMS. Uninhibited structure 1SR9
is shown in green, with leucine-bound structure 3FIG in purple. Leucine is shown in orange.
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Outside of the flexible loop, resistance to leucine may be bestowed by substitution of
the conserved residue Gly479 for cysteine in E. coli α-IPMS (Gly622 inMtuIPMS).70
Resistance to leucine is also observed in the S. cerevisiae substitution of Ser519 for
threonine (equivalent to leucine-binding residue Ala536 in MtuIPMS), and enzyme
activity is increased slightly in the presence of leucine in this variant.69 Additionally,
substitution of residues Glu540 or His541 in S. cerevisiae α-IPMS (Glu556 and
His557 in MtuIPMS) for lysine or proline, respectively, provides protection against
CoA-mediated inactivation.
The leucine binding arrangement in MtuIPMS is very similar to that observed for
isoleucine in L. interrogans CMS (Figure 1.12). Here, isoleucine forms two hydrogen
bonds from its carboxyl group to the main-chain amides of Asp431 and Gln495￿
(Ala536 and Ile627￿ in MtuIPMS), whereas the isoleucine amino nitrogen shares
three hydrogen bonds with the main-chain carbonyls of Thr464￿, Pro493￿ and Ala466￿
(Asp563￿, Pro625￿ and Ala565￿ in MtuIPMS). The hydrophobic end of the inhibitor
forms extensive van der Waals contacts with Tyr430, Leu451, Tyr454, Ile458￿ and
Val468￿ (Leu535, Val551, Tyr554, Ala558￿ and A567￿ in MtuIPMS). It appears that
this hydrophobic pocket dictates enzyme specificity for isoleucine over leucine, as
substitution of Val468 for alanine results in an enzyme that is inhibited by both of
these branched-chain amino acids. There is little conservation between the α-IPMS
and CMS inhibitor-binding sites, with only a tyrosine and a proline identical between
them. The one residue in MtuIPMS (Asn532) that contributes a hydrogen bond
to leucine through its side-chain, rather than main-chain, functional groups is an
aspartate in CMS, and is not in a position to interact with isoleucine.
Figure 1.12: Stereo diagram of the isoleucine binding site in L. interrogans CMS (blue),
overlaid with the leucine binding site of MtuIPMS (green). Isoleucine is shown in purple,
leucine in orange. Binding of isoleucine is indicated. Key residues are labelled for CMS (black)
and α-IPMS (grey).
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1.3 Protein allostery
Enzymes may be regulated at many points in their life cycle, from gene expression
to protein degradation. Between these two extremes they may also be regulated by
direct control of enzyme catalytic activity. Enzyme control can take many forms,
but of particular interest is allosteric regulation, wherein action on one site of the
protein may affect catalysis at a distant active site.
Two general theories of allostery were put forth in the 1960s: the Monod-Wyman-
Changeux (MWC) model (also known as the concerted model) and the Koshland-
Ne´methy-Filmer (KNF) model (also known as the sequential model). The MWC
model suggests that all proteins exist in equilibrium between interconvertible tense
and relaxed states, where the relaxed state is more receptive to substrate binding.71
Binding of an allosteric inhibitor results in a shift in this equilibrium towards the
tense state. The KNF model also posits that proteins have two conformational
states, but that binding of an allosteric effector induces a conformational change.
This induced change of state in one subunit then encourages allosteric ligand binding
in other subunits in the oligmeric structure.72 The subunits undergo conformational
changes separately, in contrast to the MWC model, in which all subunits of an
oligomer adopt the same state.
In addition to and expanding on these theories is the recent notion of “population
shift”, which states that proteins may exist in an ensemble of conformers due to
their internal motions and flexibility.73,74 Allosteric interactions may then cause a
shift in this population to a new ensemble of states.
1.3.1 General mechanisms of allostery
Triggers of allosteric regulation include phosphorylation, formation or reduction of
disulfide bonds, and binding of proteins or small molecules.75 Binding of small mo-
lecules is the most common and is the form of regulation observed in α-IPMS.
The structural effects of regulator binding vary from large changes in protein struc-
ture, to movement of a single residue, to changes so subtle they are not apparent
in structural analyses. At the more dramatic end of this spectrum is change in
oligomeric state, such as that seen for A. thaliana TD, in which isoleucine causes a
dissociation of the tetrameric enzyme to a dimeric form.76 This inhibition and disso-
ciation can be reversed by valine.7 A change in oligomerisation is also seen when ATP
phosphoribosyltransferase (ATP-PRTase) moves from an active dimer to an inactive
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hexamer upon histidine binding. Here, the change in quaternary structure acts to
block substrate access to the active site.77 A smaller-scale gating of the active site
is seen in 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) from
Thermotoga maritima, in which tyrosine binding causes a movement of the regulat-
ory domain to obstruct the active site, without otherwise affecting the tetrameric
nature of the protein.78
Ligand binding may also affect the conformation of the active site itself. An isozyme
of DAH7PS from E. coli conveys phenylalanine inhibition via the movement of four
short peptides, culminating in changes to the active site that impair competent sub-
strate binding.79 In chorismate mutase the only noticeable change to the active site
upon allosteric tyrosine binding is the insertion of a glutamate residue, which may be
enough to alter the electrostatic properties of the substrate binding pocket.80
For enzymes without any obvious regulatory structural change, it is becoming in-
creasingly apparent that regulation can be entirely driven by changes in dynamics.
This has been clearly mapped in the dimeric catabolite activator protein, in which
binding of cyclic AMP (cAMP) to one monomer enhances protein motions, negat-
ively impacting binding of cAMP to the other monomer.81
Of course, these mechanisms are not mutually exclusive, and one protein may be af-
fected by both local structural changes and collective motions in the conformational
ensemble.
1.3.2 Molecular dynamics of MtuIPMS inhibition
As mentioned above, there is very little difference between the leucine-bound and
unbound MtuIPMS X-ray crystal structures, so the mechanism of inhibition in this
enzyme is unclear. Thus it is appealing to hypothesise that leucine inhibition is
largely mediated by enzyme molecular dynamics. Solution-phase amide hydro-
gen/deuterium exchange (HDX) has been performed to elucidate possible changes in
solvent accessibility between inhibited and uninhibited enzyme. This method meas-
ures the incorporation of deuterium into backbone amide hydrogens of proteolysed
peptide fragments.82 The incorporation can then be compared between different
states of the protein to visualise changes that may be dynamic or artifactually sup-
pressed in crystal structures.
A comparison between inhibited and uninhibited α-IPMS enzymes is shown in Figure
1.13. Deuterium incorporation is decreased in much of the regulatory domain and in
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the region of subdomain II that interacts with this domain.49 Decrease in exchange
represents a shift in conformational equilibrium towards enhanced protection from
solvent upon leucine binding.
Only one peptide in the catalytic domain showed a change in deuterium exchange
upon leucine binding (residues 78–87), a peptide that includes α-KIV-binding residue
Arg80 and metal-coordinating residue Asp81, as well as conserved residues Leu79,
Gly82 and Gln84. This peptide also shows decreased deuterium exchange when
conserved subdomain I residue Tyr410 is substituted with phenylalanine.49 The
Y410F variant retains the ability to bind leucine, with a KD of 21 ± 1 ￿M, yet has a
catalytic rate similar to that of fully-inhibited wild-type MtuIPMS, so it is thought
to represent a constitutively-inhibited variant.48
While this experiment gives evidence on how feedback regulation may be transferred
from the regulatory domain to subdomain II, and how it may affect key residues in
the active site, the pathway between subdomain II and the site of catalysis remains
unclear. This is due to a lack of change in subdomain I and peptides missing from
the HDX analysis at the interface of the two subdomains.
Figure 1.13: Map of changes in hydrogen/deuterium exchange in MtuIPMS upon leucine
binding. Areas of decreased deuterium incorporation are shown in blue. α-KIV is shown in
yellow, Zn2+ in black and leucine in orange.
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1.4 Objectives of this thesis
The broad objective of this thesis is to understand the nature of allosteric regulation
in α-IPMS, including the effects of the regulatory domain itself on catalytic activity
and the importance of structural asymmetry in the enzyme. This was investigated
using α-IPMSs from the pathogensM. tuberculosis and Neisseria meningitidis .
More detailed goals of this research are:
• To expand the breadth of current α-IPMS knowledge by characterising a pre-
viously unstudied orthologue of this enzyme;
• To elucidate the importance of residues in the regulatory domain and sub-
domain II via the generation and characterisation of amino acid-substituted
variants of the enzyme;
• To describe the contributions of the regulatory domain as a whole towards
α-IPMS structure and function by characterisation of truncated variants;
• To probe the interfaces of the regulatory and catalytic halves of α-IPMS and
evaluate their importance in protein asymmetry; and
• To determine whether the asymmetry seen in the MtuIPMS crystal structures
is also seen in solution.
α-IPMS from N. meningitidis (NmeIPMS) was selected for cloning and character-
isation due to the pathogenicity of this organism. Amino acid-substituted variants
of this enzyme were generated to investigate leucine-mediated regulation.
A truncated variant of NmeIPMS, lacking the regulatory domain, was cloned and
compared to a similarly truncated variant of MtuIPMS. Structural data found for
truncated NmeIPMS were compared to existing MtuIPMS data.
Lastly, residues at the domain interfaces ofMtuIPMS were substituted in an attempt
to affect protein asymmetry. The solution-phase structures of these variants were
compared to wild-type enzyme and the existing crystal structures.
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Wild-Type α-IPMS from
Neisseria meningitidis
2.1 Overview
The first goal of this research was to clone and fully characterise wild-type α-IPMS
from N. meningitidis (NmeIPMS). This characterisation included evaluation of pro-
tein size and oligomeric structure, and examination of general structural features of
the enzyme in the presence of ligands (such as substrates or inhibitors).
The kinetics of this enzyme were elucidated, including the effect of pH on catalysis
and the Michaelis-Menten constants for the catalytic substrates (AcCoA and α-KIV).
The effects of the allosteric inhibitor leucine were also investigated.
Finally, the solution-phase structure of NmeIPMS was determined by small angle
X-ray scattering (SAXS).
27
Chapter 2
2.2 Background
N. meningitidis serotype B is the pathogen responsible for bacterial meningitis, a
disease that can lead to death or permanent disfigurement.83,84 The pathogenicity
of this organism makes it an attractive target for antibiotic development. Research
into the enzymes of N. meningitidis can thus aid future research into targeted in-
hibitors.
α-IPMS from N. meningitidis serotype B has a sequence similarity of 78% compared
with the characterised enzyme MtuIPMS. NmeIPMS is the smaller of the two, with
517 residues and a monomer mass of 56 kDa, as opposed to the 644 residues and
mass of 70 kDa forMtuIPMS. These differences in size are partially accounted for by
the presence of a 65 residue N-terminal extension in MtuIPMS, that winds over the
(β/α)8-barrel of the other monomer in the dimer (Figure 2.1). NmeIPMS also lacks
the 38-residue tandem repeat found in the MtuIPMS regulatory domain (residues
575–612; mostly undefined in structure).
Figure 2.1: Stereo view of MtuIPMS structure 1SR9 with N-terminal extension highlighted
and position of the VNTR (mostly disordered) indicated in grey. Each monomer is shown in a
different colour.
All key active-site residues in MtuIPMS are conserved in NmeIPMS, including the
metal-binding residues Asp81, His285 and His287 (Asp16, His204 and His206 in
NmeIPMS), α-KIV-binding residues Arg80 and Thr254 (Arg15 and Thr173 in Nme-
IPMS), the potential catalytic base Glu218 (Glu143) and the two crossover residues
from subdomain I, His379￿ and Tyr410￿ (His302￿ and Tyr313￿).
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The leucine binding site is less well conserved, perhaps due to the fact that most
hydrogen bonding to leucine observed in MtuIPMS is through main-chain, as op-
posed to side-chain, functional groups. The leucine binding site is explored further
in Chapter 3.
A homology model structure has been generated for NmeIPMS by Dr Wanting
Jiao, based on the (β/α)8-barrel portion of a solved, truncated NmeIPMS structure
(Section 4.2.7) and the subdomains and regulatory domain of MtuIPMS structure
1SR9.51 This homology structure compares to the MtuIPMS crystal structure with
a root mean squared (rms) difference of 1.7 A˚ for 659 Cα atoms (Figure 2.2). The
modelled NmeIPMS structure lacks the MtuIPMS N-terminal extension, and rep-
resents the complete NmeIPMS protein sequence except for a truncation of the final
thirteen residues. These C-terminal residues did not align with any correspond-
ing residues in MtuIPMS, and were unable to be satisfactorily folded within the
model.
Figure 2.2: Homology model of NmeIPMS (purple) superimposed on the crystal structure of
MtuIPMS (PDB code 1SR9 — green).
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2.3 Isolation of NmeIPMS
2.3.1 Cloning
Touchdown polymerase chain reaction (PCR) was performed to amplify the gene
leuA, encoding α-IPMS, from N. meningitidis genomic DNA. Primers designed for
PCR included a 5￿ CACC overhang for topoisomerase-mediated ligation as described
below.
The amplified PCR products were analysed by agarose gel electrophoresis, in which
the leuA sample revealed a band appropriate for a calculated size of 1558 bases,
including the 5￿ overhang (Figure 2.3).
LeuA 
2500 
2000 
1500 
1000 
750 
500 
250 
3000 
3500 
1250 
Figure 2.3: Agarose gel of cloned leuA DNA fragment. Marker sizes indicated in number of
bases.
Topoisomerase was used to ligate the leuA gene into a pET-151 vector. The en-
gineered 5￿ overhang on the PCR fragment was ligated to the 3￿ end of a region
encoding a polyhistidine tag and a tobacco etch virus (TEV) protease cleavage se-
quence (detailed below in Figure 2.6).
DNA encoding the His-tag was appended to the leuA gene in the vector to allow the
tagged protein to be easily purified. The TEV cleavage sequence allows recognition
by TEV protease, allowing the targeted cleavage of the His-tag. A T7 promoter
region binding a lac operon was also present in the plasmid, to enable over-expression
of the gene of interest under high lactose conditions, and an ampicillin resistance
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gene was included to easily select for cells possessing the plasmid by growth on
ampicillin-containing media.
E. coli BL21 One Shot TOP10 cells were transformed with the leuA-containing con-
struct, and plasmids were isolated from these cells for sequencing. Plasmid sequences
were compared to gene sequences to confirm successful PCR and ligation, and plas-
mids that were shown to include the whole, correct leuA gene were transformed into
E. coli BL21(DE3)Star cells for later protein expression.
2.3.2 Expression
Expression of NmeIPMS was carried out as described in Section 7.3.6. Cell pellets
harvested after protein expression were either lysed immediately or stored at -80 ◦C
until required. Steps from lysis to initial immobilised metal affinity chromatography
(IMAC) were performed without delay to reduce the effects of proteolysis in the
lysate. If samples of crude lysate were required to be stored for longer than an hour
then protease inhibitors were added to the lysate.
NmeIPMS 
soluble 
97 
66 
45 
31 
22 
insoluble 
Figure 2.4: SDS-PAGE of NmeIPMS over-expression. Lanes show the soluble and insoluble
fractions after cell lysis by sonication. Marker weights indicated in kDa.
Lysis was generally carried out by sonication, however larger cell cultures were occa-
sionally lysed by a high-pressure cell disruptor. Figure 2.7 shows a sodium-dodecyl-
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sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of proteins in the
soluble and insoluble fractions after protein expression and cell lysis by sonication.
The majority of over-expressed protein is found in the soluble fraction, at the ex-
pected weight of ∼60 kDa (including the 4 kDa His-tag).
2.3.3 Purification
Typical purification followed the steps outlined in Figure 2.5.
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Figure 2.5: Flow diagram of NmeIPMS purification procedure
This protocol resulted in protein of sufficient purity for all characterisation assays.
The first desalting step removes high concentrations of imidazole from the protein
solution in preparation for overnight TEV protease cleavage, while the second desalt-
ing step removes dithiothreitol (DTT) and ethylenediaminetetraacetic acid (EDTA)
from the cleavage buffer to allow for further affinity chromatography.
This procedure typically gave a final protein yield of 40mg for 1 L of lysogeny broth
(LB) cell culture.
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Immobilised metal affinity chromatography
IMAC was the first step in protein purification. Co2+-bound Talon R￿ affinity resin
was used to isolate NmeIPMS from background E. coli proteins via binding of the
engineered N-terminal His-tag. Bound protein was eluted with 150mM imidazole.
Typical unbound and bound fractions from this process can be seen in lanes 2 and
3 of Figure 2.7.
To improve the yield of tagged protein from this step, fractions of protein that did
not bind to the column were often reloaded onto the resin (following re-equilibration
in buffer with a low imidazole concentration) and a second elution performed. This
step allowed for isolation of tagged protein that may not have bound to the resin
during the first run.
Desalting
NmeIPMS was eluted from the Talon R￿ column in buffer with a high imidazole
concentration. Pooled elution fractions were thus desalted into a low-imidazole
buffer at this stage to reduce any effects of imidazole on stability and TEV protease
efficacy.
TEV protease digestion
Once in buffer with a reduced imidazole concentration, protein was digested at 4 ◦C
overnight with TEV protease to cleave the His-tag from NmeIPMS, minimising the
potential effects of this tag on protein structure and function.
The His-tag added 33 amino acid residues to the N-terminus of NmeIPMS, including
six histidine residues, to bind affinity resin, and a TEV protease recognition sequence
(Figure 2.6). After digestion, the six residues GIDPFT from this tag remained on
the N-terminus of NmeIPMS.
!""""""#$%&%'%((#()*+,'(-./#&)%.+ 
Figure 2.6: Sequence of vector pET-151 polyhistidine tag, detailing: histidine binding region
(pink); TEV protease cleavage site (blue); and post-cleavage N-terminal protein extension
(orange).
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After digestion, the protein-containing solution was again desalted, as above, to
remove the DTT and EDTA present in the digestion buffer. The protein was then
re-applied to the Talon R￿ affinity column, which this time bound the isolated tag
and the TEV protease (itself possessing a His-tag) and separated them from the
newly untagged NmeIPMS.
Lane 4 of the gel shown in Figure 2.7 shows NmeIPMS after TEV digestion and
the second IMAC separation. The single band at a decreased size from the protein
pre-TEV addition indicates that NmeIPMS has been cleaved. A faint band at the
pre-TEV protein weight can be seen in the column-bound fraction (lane 5) and
indicates that TEV cleavage was not 100% efficient. TEV protease itself is also
visible as a faint band at 28 kDa in the column-bound fraction.
Size-exclusion chromatography
The final step in purification of NmeIPMS was size-exclusion chromatography (SEC),
from which NmeIPMS eluted as a single peak. The weight of the purified protein
after this step is consistent with the calculated mass of 56 kDa (Figure 2.7).
NmeIPMS 
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Figure 2.7: SDS-PAGE of NmeIPMS purification. Marker weights indicated in kDa.
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2.4 Physical characterisation
2.4.1 Presence of secondary structure
A circular dichroism (CD) spectrum (Figure 2.8) was obtained to determine whether
purified NmeIPMS was properly folded.
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Figure 2.8: Circular dichroism spectrum of NmeIPMS
Analysis of these data on the K2D3 secondary structure server85 estimates that
the protein has a ratio of α-helix to β-strand of 1.09. This is about half the ratio
expected from the α-IPMS homology model and could indicate some disorder in the
α-helical regions of the protein, but more likely is a reflection of the highly variable
nature of secondary structure estimation.86 The presence of secondary structure in
the protein indicates that it is folded and suitable for further characterisation.
2.4.2 Molecular mass
The molecular weight of NmeIPMS was measured by electrospray mass spectro-
metry (MS). The mass for this protein was found to be 56029Da, which compares
favourably with the mass calculated from the amino acid sequence by ProtParam87
(56027Da) and the size of the band observed in SDS-PAGE (Figure 2.7).
35
Chapter 2
2.4.3 Oligomeric structure
Many α-IPMS enzymes are reported to be dimers in solution, although some may
form trimers or tetramers.41,42,46,65 The multimeric state of NmeIPMS in solution
was determined using an analytical gel-filtration column.
A standard curve was generated from proteins of known size (Table 2.1). Blue
dextran was large enough to elute at the void volume (Vo) of the column. The
standard curve was calculated from a plot of the log of protein molecular weight vs.
the ratio of elution volume (Ve) to void volume. A line of best fit for this curve was
calculated as y = −1.6x+ 7.8 with R2 = 0.98 (Figure 2.9).
Protein Molecular Weight (kDa) Ve (mL)
Carbonic Anhydrase 29 16.6
Ovalbumin 43 15.3
Bovine Serum Albumin 66 14.1
Conalbumin 75 14.4
Alcohol Dehydrogenase 150 13.1
Ferritin 440 10.4
Apoferritin 443 11.0
Thyroglobulin 669 9.5
Blue Dextran 2000 8.2
Table 2.1: Protein standards used in analytical gel-filtration chromatography
NmeIPMS eluted as a single peak at 13.3mL. The equation of the standard curve
was used to convert this to a molecular weight of 115 kDa (Table 2.2). The calculated
molecular weight of monomeric NmeIPMS is 56 kDa, so this protein appears to be
a dimer in solution.
Effects of leucine on structure
Crystal structures of MtuIPMS with leucine bound have very little structural dif-
ference from the non-leucine bound enzyme structure.51 The flexible loop over the
leucine binding site becomes more ordered, but there is no observed change to the
catalytic site and no change in oligomeric structure.
To eliminate the possibility that NmeIPMS undergoes changes in quaternary struc-
ture upon leucine binding, further analytical gel-filtration chromatography was car-
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ried out in the presence 200 ￿M L-leucine (Figure 2.9 and Table 2.2). NmeIPMS
again eluted at a volume consistent with the mass of the dimer (117 kDa). This
enzyme has residual activity of less than 50% at this leucine concentration (see
Section 2.5.2 below).
NmeIPMS, like MtuIPMS,46 appears to be a dimer in solution in the presence and
absence of the allosteric inhibitor. This precludes the possibility that inhibition is
effected by gross changes in oligomeric structure, such as the removal of subdomain I
residues from the active site by dissociation of the dimer. It is possible, however, that
at higher or lower protein concentrations different behaviour could be observed.
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Figure 2.9: NmeIPMS gel filtration in the presence and absence of 200 ￿M L-leucine. Samples
run in 50mM TrisHCl buffer (pH 7.5) with 100mM KCl. The calibration curve is shown in
black.
Molecular Weight (kDa)
Monomera Oligomerb Quaternary Structure
NmeIPMS 56 115 dimer
NmeIPMS + leu 56 117 dimer
Table 2.2: Oligomeric structure of NmeIPMS in the presence and absence of 200 ￿M L-leucine.
Samples run in 50mM TrisHCl buffer (pH 7.5) with 100mM KCl. aCalculated based on se-
quence; bDetermined from calibration curve.
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2.4.4 Thermal stability
Differential scanning fluorimetry (DSF) was used to investigate the stability of Nme-
IPMS in the presence of substrates and inhibitor. DSF uses a dye that fluoresces in
the presence of hydrophobic amino acids to monitor protein denaturation. As the
protein is heated, the internalised, hydrophobic residues are exposed to the dye, and
fluorescence increases. Thus the temperature of denaturation can be determined as
the point of greatest increase in fluorescence (Figure 2.10).
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Figure 2.10: Example of a thermal denaturation curve produced by DSF, where RFU is relative
fluorescence units. The negative of the first derivative is shown in red on the secondary axis. Tm
is indicated by the point of greatest increase in fluorescence, or the minimum of the derivative.
DSF shows that NmeIPMS has a denaturation temperature of 44.5 ± 0.1 ◦C (Figure
2.11 and Table 2.3 ). This temperature is low compared to the N. meningitidis
growth environment of 37 ◦C and the in vitro activity optimum of 40 ◦C for this
enzyme.63 It is likely that other factors present in the N. meningitidis cell increase
stability, and other studies have shown that metal ions may contribute to this (see
Section 2.7.1).63 Noticeable increases in the denaturation temperature of NmeIPMS
are observed in the presence of the substrate α-KIV or the inhibitor leucine (Figure
2.11). Leucine in combination with either substrate confers greater stability than
either ligand alone. AcCoA has a minimal effect on this enzyme stability.
DSF can also be used as an indicator of ligand binding, if it is assumed that such
binding has an effect on overall protein stability. The effects of amino acids isoleu-
cine, valine and glycine were thus compared to that of leucine to give some measure
of inhibitor specificity (Figure 2.12). While increasing concentrations of leucine
give steadily increasing denaturation temperatures, isoleucine and glycine show no
38
Wild-Type α-IPMS from Neisseria meningitidis
significant effects while valine confers a modest increase in stability only at high
concentration.
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Figure 2.11: Denaturation temperatures of NmeIPMS in the presence and absence of bio-
logical substrates (250 ￿M each) and inhibitor (1mM). All samples in 25mM BTP buffer
(pH 7.0).
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Figure 2.12: NmeIPMS denaturation temperatures in the presence of amino acids L-leucine,
L-isoleucine, DL-valine and glycine. All samples in 25mM BTP buffer (pH 7.0).
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Ligand(s) Tm (◦C)
No ligand 44.5 ± 0.1
biological ligands
250 ￿M α-KIV 51.2 ± 0.4
250 ￿M AcCoA 46.1 ± 1.1
1mM L-leucine 59 ± 3
250 ￿M α-KIV + 1mM L-leucine 61.3 ± 0.5
250 ￿M AcCoA + 1mM L-leucine 62.0 ± 0.9
amino acids
200 ￿M L-leucine 52.2 ± 0.5
1mM L-leucine 59 ± 3
2mM L-leucine 65.2 ± 0.2
200 ￿M L-isoleucine 43.9 ± 0.4
1mM L-isoleucine 44.3 ± 0.5
2mM L-isoleucine 44.6 ± 0.1
200 ￿M DL-valine 46.0 ± 0.5
1mM DL-valine 46.5 ± 0.1
2mM DL-valine 53 ± 1
200 ￿M glycine 48 ± 2
1mM glycine 48.6 ± 0.7
2mM glycine 46.6 ± 0.1
Table 2.3: Denaturation temperatures (Tm) of NmeIPMS in the presence of potential ligands.
All samples in 25mM BTP buffer (pH 7.0).
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2.5 Kinetic characterisation
The activity of NmeIPMS was studied in two parts: first the catalytic constants
were calculated for the two substrates (α-KIV and AcCoA), and then the effects of
leucine on catalysis were investigated.
The majority of these kinetic assays were carried out using a 4,4￿-dithiodipyridine
(DTP)-coupled assay, monitoring absorbance at 324 nm. This measured the genera-
tion of a thio-pyridine by reaction of DTP with the free thiol of the enzyme product
CoA.
2.5.1 Michaelis-Menten kinetics
The turnover number and apparent Km values were found for NmeIPMS at 25 ◦C
(Figure 2.13). Details of these data can be found in Table 2.4. These values show
that NmeIPMS has a lower affinity for α-KIV and a higher affinity for AcCoA than
MtuIPMS.46
(a) AcCoA Michaelis-Menten plot (b) α-KIV Michaelis-Menten plot
Figure 2.13: Plots of kinetic data for NmeIPMS, showing variation in initial reaction rate
with change in substrate concentration. Inset: Lineweaver-Burk plots of data.
NmeIPMS was also found to hydrolyse AcCoA independently of α-KIV. This un-
coupled hydrolysis occurred at a rate 1000-fold slower than the condensation re-
action, and had almost 10-fold decreased affinity for the substrate. These kinetic
parameters are similar to those found for this reaction inMtuIPMS.46 The uncoupled
hydrolysis of AcCoA in NmeIPMS was not affected by L-leucine at concentrations
up to 10mM.
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NmeIPMS MtuIPMS46
normal catalysis
Kappm for α-KIV (￿M) 30 ± 2 12 ± 1
Kappm for AcCoA (￿M) 35 ± 3 136 ± 5
kcat (s−1) 12.8 ± 0.3 3.5 ± 0.1
uncoupled AcCoA hydrolysis
Kappm for AcCoA (￿M) 250 ± 30 160 ± 29
kcat (s−1) 0.011 ± 0.001 0.03 ± 0.002
Table 2.4: Kinetic data for NmeIPMS and MtuIPMS.46 For normal catalysis, invariant sub-
strate was held at a concentration of 250 ￿M. Uncoupled AcCoA hydrolysis indicates values
obtained in the absence of α-KIV.
2.5.2 pH dependence
NmeIPMS activity varies with pH, with maximal activity observed at pH8.5 (Figure
2.14). Assays were carried out using a direct assay at 232 nm, measuring the loss of
AcCoA, as high pH caused the reaction of DTP and CoA to become rate limiting.
Due to high AcCoA absorbance at 232 nm, non-saturating (80 ￿M) concentrations of
this substrate were used. de Carvalho et al. have previously established that Mtu-
IPMS has maximal kcat values from pH6.7–9.0 using the DTP-coupled assay.46
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Figure 2.14: Effects of pH on NmeIPMS catalytic activity. Residual activity is normalised to
the maximal acitivity seen (pH 8.5). Samples in BTP (blue) or MES buffer (red).
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2.5.3 Allosteric inhibition
NmeIPMS, like MtuIPMS, exhibits inhibition by leucine, the end-product of the
α-IPMS metabolic pathway. Leucine inhibition of NmeIPMS was characterised with
respect to inhibition constants, time dependence and pH dependence.
Kinetic parameters
(a) AcCoA inhibition plot (b) α-KIV inhibition plot
Figure 2.15: Plots for leucine inhibition of NmeIPMS. L-Leucine concentrations (from top to
bottom) are 0 ￿M, 20 ￿M, 50 ￿M, 100 ￿M and 200 ￿M. 250 ￿M of each substrate was used.
In NmeIPMS, inhibition by leucine fits a mixed, non-competitive model with respect
to both α-KIV and AcCoA (Figure 2.15), with Ki and K ￿i values as indicated in
Table 2.5. These data show that leucine inhibition is more acute with respect to
AcCoA than α-KIV, and that the affinities of leucine for free and substrate-bound
enzyme are very similar. These affinities are also very similar to those found for
MtuIPMS.45
MtuIPMS45 NmeIPMS
α-KIV α-KIV AcCoA
Ki (￿M) 22 ± 2 57 ± 23 8 ± 1
K ￿i (￿M) 8 ± 1 18 ± 2 52 ± 17
Table 2.5: L-Leucine inhibition data for NmeIPMS
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Some inhibition of NmeIPMS catalytic activity was also observed for high con-
centrations of valine, with 1mM DL-valine causing a drop in activity of 6%. No
inhibition was observed for L-isoleucine or glycine at concentrations of up to 2mM.
It appears that feedback inhibition in this enzyme is highly selective in its amino
acid sensitivity.
Time dependence
One of the noteworthy features of the leucine-mediated inhibition of MtuIPMS is
the time-dependency observed. In the presence of L-leucine, reactions catalysed by
MtuIPMS showed an initial burst of product formation, followed by a slower, linear
rate.45 This time dependence was not evident for leucine inhibition of NmeIPMS.
CoA formation by NmeIPMS was measured, via its reaction with DTP, in the
presence of saturating concentrations of substrates and metal ions, and 0–500 ￿M
L-leucine. No obvious change in CoA production rate can be seen over a 9min
reaction period (Figure 2.16), which is in contrast to results reported for MtuIPMS,
where a noticeable decrease in enzyme activity over the course of a few minutes was
observed.45
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Figure 2.16: Leucine inhibition of NmeIPMS over time. Legend shows leucine concentration
in ￿M. 250 ￿M of each substrate was used.
The transition in MtuIPMS from a Enz·Leu complex to a more tightly bound
Enz*·Leu complex is mediated by the flexible loop covering the leucine binding
site.44 Aside from a conserved glycine, the residues in this loop are poorly conserved
between species (Figure 2.17), and it is possible that slow-onset regulation in α-IPMS
is unique to M. tuberculosis .
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M. tuberculosis 549 V A V L D Y Y E H A M S A G D D A Q A A A Y V E A S V 575
N. meningitidis 447 A A L Q I Y S V N A V T Q G T E S Q G E T S V R L A R 473
C. glutamicum 513 V E I Q E Y N Q H A R T S G D D A E A A A Y V L A E . 538
E. coli 444 V E L V K Y S L T A K G H G K D A L G Q V D I V A N Y 470
S. typhimurium 444 V E L V K Y D L N A K G Q G K D A L G Q V D I V V N H 470
S. cerevisiae 533 F A V A N Y T E H S L G S G S S T Q A A S Y I H L S Y 559
N. crassa 521 L D V Q D Y K E H A V G R G R D V K A A T Y I E C T A 547
A. thaliana 1 542 A T L L E Y S M N A V T E G I D A I A T T R V L I R G 568
A. thaliana 2 540 A T L L E Y S M N A V T E G I D A I A T T R V L I R G 566
Figure 2.17: Conservation of residues in the regulatory loop. Absolutely conserved residues
are shown in red, strongly conserved residues in orange, and conserved branched-chain amino
acids in green. Boxed residues are those found in the MtuIPMS regulatory loop.44,51
pH dependence
The inhibition of NmeIPMS by leucine varies with pH, with the enzyme exhibit-
ing enhanced inhibitor sensitivity in more acidic enrivonments (Figure 2.18). As-
says were carried out at pH6.5, 7.5 and 8.5, with concentrations of L-leucine from
0–2mM. 200 ￿M inhibitor caused a loss of 20% maximal NmeIPMS activity at
pH8.5, but a loss of 89% activity at pH6.5. At the highest concentration assayed
(2mM), leucine reduced activity by 50% at pH8.5 and 95% at pH6.5.
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Figure 2.18: pH dependence of NmeIPMS L-leucine inhibition at 80 ￿M AcCoA and 250 ￿M
α-KIV. Legend indicates pH.
Such pH dependence of allosteric regulation has also been established for α-IPMSs
from Saccharomyces sp.58 and S. typhimurium,53 the latter of which was found to
be 30-fold more sensitive to leucine inhibition at pH6.5 than at pH8.5.
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2.6 Small angle X-ray scattering
SAXS data were collected for NmeIPMS in the presence and absence of 1mM
L-leucine. These data were compared to investigate potential changes in protein
solution-phase structure upon inhibitor binding.
2.6.1 Sample validation
Aggregation of samples was assessed by examining Guinier distributions of the data
(Figure 2.19). These plots indicate aggregation by the presence of a non-linear
dependence of the log of intensity vs. s2. Unfortunately the leucine-bound sample
showed signs of aggregation on this plot and no further interpretation of data was
performed. Estimates of the radius of gyration (Rg) and the intensity at s = 0 (I(0))
were calculated from this distribution (Table 2.6).
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Figure 2.19: Guinier distributions of NmeIPMS SAXS data
2.6.2 Structure parameters
A pair-distribution function (P (r) — Figure 2.20) was generated for the ligand-
free NmeIPMS data. Rg and I(0) were calculated from this plot and compared
well with those calculated from the Guinier distribution. The agreement between
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these two sets of values is another indication that the sample was not affected by
aggregation.
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Figure 2.20: Pair-distribution function of NmeIPMS SAXS data. P (r) function normalised
to 1.
The P (r) distribution also allowed for the calculation of the maximum dimension of
the molecule (Dmax) and the Porod estimate of excluded volume (Table 2.6). This
latter value is approximately proportional to the particle molecular mass, and this
indicates that the protein is a dimer in the sample (Table 2.6). This is in agreement
with the results from analytical gel-filtration experiments.
NmeIPMS
structural parameters
I(0) (cm−1) 0.104 ± 0.004
from Guinier 0.102 ± 0.000
Rg (A˚) 34.1 ± 0.1
from Guinier 32.9 ± 0.2
Dmax (A˚) 108.5
Porod volume estimate (A˚3) 186000
molecular mass estimate
mass estimate from Poroda (Da) 116000
monomeric mass from sequence (Da) 56000
likely oligomeric structure dimer
Table 2.6: SAXS parameters for NmeIPMS. Data collected at a wavelength of 1.127 A˚.
aParticle mass is roughly related to Porod volume by a factor of 0.625.88
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2.6.3 Comparison to homology model
Theoretical scattering patterns from the NmeIPMS homology model dimer and each
of its constituent monomers were fitted to the experimental data with CRYSOL89
(Figures 2.21 and 2.22). Fitting both dimer and monomer structures allows ad-
ditional confirmation of the oligomeric structure present in the SAXS experiment.
Theoretical scattering from each monomer was fitted separately, as each monomer
adopts a markedly different conformation in the asymmetric crystal structure. The
best fit to the experimental data was observed for the dimer, confirming that this is
the oligomeric structure observed in solution. The similarity between the theoretical
and experimental scattering patterns suggest that the NmeIPMS homology model
dimer is a good representation of the solution-phase structure of the protein.
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Figure 2.21: Fit of theoretical scattering from homology model dimer to NmeIPMS SAXS
data. Fit from the model dimer is shown in black (χ = 1.16). Experimental data are shown
in blue, with error bars in grey.
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Figure 2.22: Fit of theoretical scattering from homology model monomers to NmeIPMS
SAXS data. Fits of each monomer are shown in black (χ = 13.1) and green (χ = 10.9).
Experimental data are shown in blue, with error bars in grey.
49
Chapter 2
2.6.4 Theoretical domain movement in NmeIPMS
Due to the asymmetry in the α-IPMS dimer, it is tempting to postulate a hypothet-
ical movement of the C-terminal domains relative to the N-terminal barrel. This
could take the form of an oscillation from one asymmetric state to the other, in
which the monomers have exchanged conformations (Figure 2.23). Such an oscilla-
tion would represent a movement of up to 80 A˚ for individual residues in MtuIPMS,
and would be energetically unfavourable unless it conferred some advantage on the
enzyme. Movement between these conformational extremes or to a more symmet-
rical state could play a role in α-IPMS catalysis or feedback inhibition.
Figure 2.23: Stereo view of the potential movement of the α-IPMS regulatory domain.
Overlay of two dimers of MtuIPMS, rotated 180◦ relative to each other and aligned by (β/α)8-
barrels.
A simulated model of domain movement was created to compare with experimental
SAXS data, and perhaps provide insight into the solution-phase structure of the
protein. Twenty model structures were generated, representing the movement from
the structure seen in the homology model to the diametrically opposite dimer con-
formation. The end-point structures and a symmetrical mid-point structure are
shown in Figure 2.24. Theoretical SAXS curves were generated for each of these
twenty models (Figure 2.25), but these show little difference between the structures.
Therefore, this technique cannot elucidate the asymmetry present in NmeIPMS in
solution.
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(a) Model1 — Initial structure
(b) Model10 — Mid-point of potential movement
(c) Model20 — End-point of potential movement
Figure 2.24: Morph models of the potential movement of α-IPMS regulatory domain. Three
model dimers from the twenty generated across the movement are shown. Each monomer is
shown in a different colour.
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2.7 Complementary characterisation of
NmeIPMS
Additional characterisation of NmeIPMS has been performed by Michael Hunter;63
this is summarised here as it contributes to the understanding of NmeIPMS. This
has revealed that NmeIPMS has an activity maximum at a temperature of 40 ◦C,
and is not sensitive to the CoA product inhibition observed in S. typhimurium and S.
cerevisiae.60,61 This research has also elucidated the metal and α-keto acid specificity
of the enzyme.
2.7.1 Metal dependence
As with most forms of α-IPMS that have been characterised to date, NmeIPMS
displays activation by divalent metals.41,43,47 Mg2+, Mn2+, Co2+ and Ni2+ are ac-
tivating, with Mg2+ having the greatest effect. Only Mg2+ shows simple saturation
kinetics for NmeIPMS, whereas other divalent metals have distinct activity maxima,
and are less activating at concentrations greater than 200 ￿M. NmeIPMS shows no
activation by monovalent cations at any concentration. This is in contrast to Mtu-
IPMS, which demonstrates a strong correlation between monovalent cation concen-
tration and activity, despite the fact that MtuIPMS has no obvious binding site for
such a cation.47
Analysis of NmeIPMS thermal stability in the presence of divalent metal ions shows
that 5mM Mn2+, Co2+, Ni2+ or Zn2+ increases the denaturation temperature of the
enzyme by 10–14 ◦C, whereas Mg2+ and Cd2+ have no effect. None of these metal
ions significantly altered NmeIPMS denaturation temperature at lower concentra-
tions (250 ￿M).
2.7.2 Substrate specificity
NmeIPMS exhibits a similar α-keto acid specificity to MtuIPMS. α-KB and α-keto-
valerate have similar turnover rate to the natural substrate (α-KIV) in NmeIPMS,
but lower affinity, whereas pyruvate has both lower affinity and rate. α-Keto-β-
methylvalerate is a weak substrate, whereas glyoxalate and oxaloacetate are weak
inhibitors. In MtuIPMS, no activity is observed for α-keto-β-methylvalerate or gly-
oxalate.46 NmeIPMS, like MtuIPMS,46 is competitively inhibited by (S)-α-hydroxy-
isovalerate.
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2.8 Summary of findings
NmeIPMS was successfully cloned, expressed and purified by metal-affinity and size-
exclusion chromatography. A CD spectrum indicates this protein is properly folded,
and MS shows it is of the appropriate size. This protein exhibits similar properties
to other characterised α-IPMS orthologues.
NmeIPMS is a dimer in solution in the presence and absence of leucine, as is Mtu-
IPMS46 and one isozyme of α-IPMS from A. thaliana. Other α-IPMSs have been
observed as trimers and tetramers.41,42,65
The denaturation temperature of NmeIPMS is 44.5 ± 0.1 ◦C, which is low com-
pared to the 37 ◦C growth environment for the enzyme. This low thermal stability
is perhaps due to the absence of metal ions in the experimental conditions, as these
have been shown to increase NmeIPMS stability significantly.63 Increased structural
stability of NmeIPMS is observed in the presence of the allosteric inhibitor L-leucine
or the substrate α-KIV. The denaturation temperature of the enzyme increases by
6.7 ± 0.5 ◦C in the presence of 250 ￿M α-KIV, and by 7.7 ± 0.6 ◦C in the presence of
200 ￿M L-leucine. Increase in enzyme stability was also seen at high concentrations
of DL-valine, and this amino acid shows some inhibition of NmeIPMS, decreasing
enzyme activity by 6% at a concentration of 1mM. No increased stability or en-
zyme inhibition is observed for NmeIPMS in the presence of L-isoleucine or glycine,
indicating that feedback inhibition and perhaps allosteric binding is highly selective
in this enzyme. These results are similar to those for CMS, which shows inhibitor
selectivity for isoleucine over leucine.9
Michaelis-Menten kinetic parameters for NmeIPMS were found to be similar to
those for other α-IPMSs (see Table 1.2 in Section 1.2.1), with binding affinities in
the micromolar range and a turnover number of 13 s−1. NmeIPMS has a pH activity
maximum of 8.5, as observed for other bacterial α-IPMSs.41,53,57 Like MtuIPMS,46
NmeIPMS is able to catalyse the hydrolysis of the substrate AcCoA in the absence
of α-KIV, with reduced AcCoA affinity and a dramatically impaired rate.
Again similar to MtuIPMS, NmeIPMS is inhibited by leucine in a mixed, non-
competitive manner, however NmeIPMS does not demonstrate the time-dependency
of inhibition observed for the M. tuberculosis enzyme.45 NmeIPMS exhibits pH-
dependent sensitivity to leucine inhibition, as observed for Saccharomyces sp. and
S. typhimurium,53,58 and is almost five times more sensitive to 200 ￿M L-leucine at
pH6.5 than at pH8.5.
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SAXS data show that NmeIPMS adopts a similar conformation in solution to that
of the enzyme homology model and, by extension, the MtuIPMS crystal structure
the model is based upon. Potential domain movement in the asymmetric dimer
was investigated by construction of morphed structural models, however theoretical
scattering patterns from these showed no significant changes, and thus SAXS could
not be used to assess the asymmetry of the experimental sample.
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Leucine Inhibition in NmeIPMS
3.1 Overview
NmeIPMS is inhibited by the branched-chain amino acid leucine. This chapter
describes experiments conducted to understand this inhibition. Several residues of
NmeIPMS were substituted for this purpose.
Residue Ser429 was substituted for alanine in an attempt to directly disrupt leucine
binding, whereas residues Pro431 and Thr491 were replaced by glycine and alanine,
respectively, to better understand the subtleties of structure surrounding the leucine
binding site. Substitutions of residues Gly482 and Arg336 to proline and alanine
were performed to elucidate the mechanism of transfer of inhibitory signal from the
allosteric regulatory site to the catalytic (β/α)8-barrel.
Enzyme activity and inhibition were investigated for each of these variants.
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3.2 Background
3.2.1 Leucine binding in α-IPMS
As the first committed step of leucine biosynthesis, the reaction catalysed by α-IPMS
is controlled by feedback inhibition from the end-product of this pathway. The
binding of leucine in the regulatory domain of MtuIPMS has been elucidated by
crystallographic studies (PDB code 3FIG).51
Figure 3.1: Stereo diagram of leucine binding in MtuIPMS structure 3FIG. Each monomer is
shown a different colour. Leucine is shown in orange.
In structure 3FIG of MtuIPMS, the amino/carboxylate end of leucine forms hydro-
gen bonds with four residues. Residue Asn532 (equivalent to Ser429 in NmeIPMS)
forms a hydrogen bond from its side-chain carbonyl to the amino group of leu-
cine, while Ala536, Ala565￿ and Ile627￿ (Asp433, Ser463 and Val487 in NmeIPMS)
form hydrogen bonds to the inhibitor through their main-chain functional groups,
as shown in Figure 3.1. Four other residues form the hydrophobic pocket around the
methyl groups of leucine — Leu535, Val551, Tyr554 and Ala558￿ (Val432, Leu449,
Tyr452 and Ala456 in NmeIPMS).
Unfortunately some of the secondary structure around the leucine binding site is
ill-defined in the NmeIPMS homology model, and some side chains of residues that
are in theMtuIPMS leucine binding site are oriented away from this site in the Nme-
IPMS model. For this reason, and the fact that the model does not show leucine
bound, all NmeIPMS residues substituted in this chapter were selected based on the
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MtuIPMS leucine-bound structure and a multiple sequence alignment (see Figure
3.7 and Appendix A).
3.2.2 Structural elements in the regulatory domain
The leucine binding site in the MtuIPMS dimer is comprised of residues from the
ends of two α-helices (one from each monomer), one β-strand and the flexible loop
associated with slow-onset feedback inhibition (Figure 3.2).
!14 
!15 
"14 
flexible loop 
Figure 3.2: Secondary structure in the leucine binding site of MtuIPMS structure 3FIG. Key
structural elements are shown in a different colour for each monomer. Leucine is shown in
orange.
At the N-terminal start of one of these helices (α14 in Figures 3.2 and 3.7) is a G-
x-G-P-[VIL] motif that contributes two residues to the regulatory site; in MtuIPMS
the motif residues are Gly531-Asn532-Gly533-Pro534-Leu535 (Figure 3.3), whereas
in NmeIPMS they are Gly428-Ser429-Gly430-Pro431-Val432. This motif appears
to be highly important for enzyme regulation: substitution of either of the glycines
(for aspartate) in S. cerevisiae α-IPMS results in a leucine-insensitive enzyme,69 as
does substitution of the proline for leucine in E. coli α-IPMS.70
The first of the NmeIPMS substitutions described in this thesis is of Ser429, the
variable residue in the G-x-G-P-[VIL] motif and equivalent to MtuIPMS residue
Asn532, which forms a hydrogen bond from its carbonyl group to the amino group
of leucine (Figures 3.1 and 3.3). The amino acids asparagine or threonine are usually
found at this position in α-IPMSs from other organisms. Ser429 in NmeIPMS was
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Figure 3.3: Stereo diagram of the G-x-G-P-[VIL] motif in MtuIPMS structure 3FIG. Each
monomer is shown in a different colour. Leucine is shown in orange.
substituted for alanine to remove the serine side-chain functionality, and assess the
importance of this potential hydrogen bond in NmeIPMS sensitivity to leucine.
The second NmeIPMS substitution made was of Pro431, the conserved proline in
the G-x-G-P-[VIL] motif. Proline is unique amongst the natural amino acids in
that its main-chain torsion angle is restricted to about -60◦. This dihedral angle
constriction is likely important for the backbone structure of the motif loop. Pro431
was substituted for glycine in NmeIPMS, which has no dihedral angle restriction.
This substitution represents a complete loss of backbone conformation restriction at
this position. Although a substitution of the motif proline has already been made
in E. coli α-IPMS, this previous replacement was with leucine. Leucine has less
torsion angle restriction than proline but more than glycine, and also has a bulky
hydrophobic side chain that may have additional effects on the enzyme structure.
A substitution to glycine frees the main-chain angle restraint of the residue without
adding side-chain functionality.
At start of the other leucine-binding-site helix (α15 in Figures 3.2 and 3.7) sits residue
Ile627 (Val487 in NmeIPMS), which contributes both hydrogen-bonding contacts
and hydrophobic contacts to the binding of the inhibitor (Figures 3.1 and 3.4). The
main-chain carbonyl of this residue, and of its neighbour Thr628, are stabilised
by intra-helix hydrogen bonding to the side-chain hydroxyl and main-chain amino
group of Ser631 (Figure 3.4). This serine is highly conserved across α-IPMSs and
could ensure correct positioning of Ile627 in the binding pocket. Thr628, on the
other hand, is poorly conserved, and equates to residue Leu488 in NmeIPMS.
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Ser631 is the equivalent of Thr491 in NmeIPMS; to determine the importance of this
residue in protein function and leucine sensitivity, this threonine was substituted for
alanine.
Figure 3.4: Stereo diagram of stabilisation of Ile627 in MtuIPMS structure 3FIG. Each
monomer is shown in a different colour. Leucine is shown in orange.
3.2.3 Communication between α-IPMS domains
Multiple sequence alignments reveal that there are two conserved glycines on β-
strand β16 in the regulatory domain (Figures 3.5 and 3.7). These glycines are not
in direct contact with the leucine binding site, but the strict conservation suggests
that they have some functional or structural importance. This β-strand lies at the
interface of the regulatory domain and subdomain II, and substitution of one of the
glycines for cysteine in E. coli α-IPMS results in a leucine-resistant variant.70
The regulatory domain to subdomain II interface is composed of hydrophobic inter-
actions from very poorly conserved residues. The flexibility of the conserved glycines
could be necessary to allow the surrounding hydrophobic side chains to optimally
interact. InMtuIPMS, the lack of a side chain for these glycine residues (Gly620 and
Gly622) may also be important for the correct positioning of a conserved alanine
(Ala634) that hydrogen bonds to residue Ser631. Through this serine, these gly-
cines may influence the positioning of leucine-binding residue Ile627, as described
above. The Gly622 equivalent in NmeIPMS (Gly482) was substituted for proline
to restrict the main-chain torsion angle and add to the steric bulk at this position.
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This substitution probes the structural importance of flexibility and small size in
this residue.
Figure 3.5: Stereo diagram of structural elements at the regulatory to subdomain II interface
of MtuIPMS structure 3FIG. One monomer is shown in white, the other is coloured by domain:
regulatory domain in purple, subdomain II in pink. The leucine binding site is at the interface
of the purple and white regulatory domains, to the left of frame in this diagram.
The final substitution made in NmeIPMS was designed to probe potential com-
munication between subdomain II and the catalytic domain. This interface was
explored as it seems the most direct pathway for leucine-mediated inhibition to
affect the active site.
In MtuIPMS, Lys434 is at the start of subdomain II, and may interact with Asp88,
Arg94 or Gln357 in the catalytic (β/α)8-barrel, although its side chain is undefined
in existing crystal structures (Figure 3.6). Of all the residues in MtuIPMS subdo-
main II that are positioned to interact with the catalytic domain (including Tyr439
and Glu474), it is the most conserved, appearing as lysine or arginine across all
α-IPMS sequences. This residue is an arginine in NmeIPMS (Arg336). This was
substituted for alanine to examine the importance of the long, basic side chain at
this interface.
The interface of the catalytic domain with subdomain II inMtuIPMS is investigated
in Chapter 5.
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Figure 3.6: Stereo diagram of the subdomain II to catalytic domain interface in MtuIPMS
structure 3FIG. The side chain of Lys434 (undefined in the crystal structure) has been built
in two possible rotomers. One monomer is shown in white, the other is coloured by domain:
subdomain II in pink and the catalytic domain in green.
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Figure 3.7: Sequence logo of subdomain II and the regulatory domain of α-IPMS. Bottom
numbering is forMtuIPMS, with asterisks representing residues involved in leucine binding, and
illustrations showing key secondary structure elements in the regulatory domain. NmeIPMS
residues substituted in this chapter are indicated. Sequences used in construction of this logo
are shown in Appendix A.
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3.3 Preparation of NmeIPMS variants
3.3.1 Cloning
Amino acid substitutions S429A, P431G, G482P, T491A and R336A were generated
by introducing the appropriate base-pair changes into the plasmid encoding wild-
type NmeIPMS.
The mutant plasmids were transformed into E. coli XL1 Blue cells, sequenced,
and finally transformed into E. coli BL21(DE3)Star cells as for the wild-type plas-
mid.
3.3.2 Expression and purification
Proteins were expressed and purified as for wild-type protein. Variants S429A,
P431G, T491A and R336A appeared pure and of a comparable size to wild-type
protein by SDS-PAGE.
Variant G482P appeared as a series of bands in SDS-PAGE analysis, even after
purification by SEC, and appears to suffer from proteolysis during expression. This
proteolysis could be in response to misfolding of the enzyme, which could be due to
the structural changes (such as change in main-chain torsion angle or steric bulk)
incurred by the glycine to proline substitution. This protein was assessed for activity
(see Section 3.5) but was not characterised further than this.
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Figure 3.8: SDS-PAGE of NmeIPMS variants. Marker weights indicated in kDa.
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3.4 Physical characterisation
3.4.1 Presence of secondary structure
CD analysis shows that variants S429A, P431G, T491A and R336A all adopt similar
folds to that of wild-type protein (Figure 3.9). G482P was not assessed by CD due
to the degradation observed by SDS-PAGE analysis.
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Figure 3.9: Circular dichroism spectra for NmeIPMS variants, compared to spectrum of
wild-type protein
3.4.2 Molecular mass
All un-proteolysed variants appear to be of an appropriate mass as measured by
MS.
Calculated Mass (Da) Experimental Mass (Da)
S429A 56011 56010
P431G 55987 55986
T491A 55997 55998
R336A 55942 55941
Table 3.1: Calculated and experimental masses of NmeIPMS variants
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3.4.3 Thermal stability
All amino-acid substituted variants of NmeIPMS showed similar thermal stability
to the wild-type protein, as determined by DSF (Table 3.2). The largest change
in stability was observed for variant P431G, which showed a 3.9 ◦C decrease in
denaturation temperature when compared to wild-type NmeIPMS. It appears that
the proline to glycine substitution effects the flexibility of the protein as a whole, in
addition to any effects it may have at the site of subsitution.
Tm (◦C)
NmeIPMS 44.5 ± 0.1
S429A 45.9 ± 0.3
P431G 40.6 ± 0.7
T491A 45.9 ± 0.1
R336A 42.7 ± 0.2
Table 3.2: Denaturation temperatures (Tm) of NmeIPMS variants in 25mM BTP buffer
(pH 7.0), compared to that of wild-type protein.
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3.5 Kinetic characterisation
3.5.1 Michaelis-Menten kinetics
Michaelis constants and comparative inhibition data were found for the variants
S429A, P431G, T491A and R336A. These variants are all catalytically active with
similar turnover numbers to wild-type enzyme. T491A and R336A exhibit slightly
decreased maximum rates of catalysis, whereas S429A shows some increase in cata-
lytic activity.
The substitutions present in the NmeIPMS variants have minimal effect on α-KIV
affinity. In S429A and P431G this affinity is unchanged, whereas in the other two
variants a slight decrease in affinity is observed. The most noticeable change between
wild-type NmeIPMS and these variants is in the reduction of AcCoA affinity. This
reduction is largest in P431G and R336A, highlighting the importance of these
residues, as discussed below.
G482P was not fully characterised due to the multiple breakdown products seen by
SDS-PAGE. Kinetic testing shows it has a turnover rate of 1.6± 0.05 s−1 at substrate
concentrations of 500 ￿M, which are saturating concentrations for wild-type protein.
Some functional enzyme is thus still present in solution.
Kappm (￿M) kcat/Km (mM−1s−1)
α-KIV AcCoA kcat (s−1) α-KIV AcCoA
NmeIPMS 30 ± 2 35 ± 3 12.8 ± 0.3 430 ± 40 370 ± 40
S429A 33 ± 3 45 ± 4 20.6 ± 0.4 640 ± 70 470 ± 50
P431G 28 ± 3 114 ± 18 11.6 ± 0.3 430 ± 60 110 ± 20
T491A 64 ± 7 60 ± 7 7.4 ± 0.2 110 ± 20 120 ± 20
R336A 48 ± 5 800 ± 190 7.0 ± 0.7 150 ± 30 9 ± 3
Table 3.3: Kinetic data for wild-type and variant NmeIPMS
The variant P431G has a three-fold higher Kappm for AcCoA than wild-type. This
substitution removes the main-chain torsion constriction of the proline residue, po-
tentially affecting the structure of the leucine binding site. As proline is often a
key structural element due to its rigid backbone chirality, it is tempting to hypo-
thesise that disruption of structure in the regulatory domain has a flow-on effect
through subdomain II to subdomain I, which contributes to the AcCoA binding
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pocket in the active site. Any changes to protein structure are likely subtle, in
light of the similarity in other kinetic parameters and CD spectrum to those of the
wild-type.
The R336A substitution decreases affinity of the enzyme for AcCoA 23-fold, despite
being located at least 20 A˚ from the substrate binding site. This arginine residue
may interact with a number of residues in C-terminal loops of the catalytic (β/α)8-
barrel, some of which are adjacent to the AcCoA binding site. Thus, the interactions
between Arg336 and the catalytic domain could act to appropriately configure the
active site for AcCoA binding.
3.5.2 Allosteric inhibition
Inhibition by leucine seems relatively unchanged in R336A compared with wild-type
NmeIPMS (Figure 3.10), but variants S429A and T491A show large desensitisation
to leucine, and variant P431G demonstrates almost no sensitivity to this ligand at
all.
The effect of substrate concentration on leucine sensitivity in these NmeIPMS vari-
ants was investigated, and all variants show similar trends to the wild-type in this
regard. The reduction in leucine sensitivity observed for S429A and T491A confirms
the importance of residues Ser429 and Thr491 in NmeIPMS leucine binding. In fact,
the loss of leucine sensitivity is very similar for both these variants, despite the fact
that Ser429 is likely directly involved in leucine binding, whereas Thr491 plays a
secondary role in stabilising a binding residue. This highlights the importance of the
residues surrounding the leucine binding pocket in correctly positioning the binding
residues themselves.
Almost no inhibition is detectable in variant P431G, indicating that the binding-
motif proline is critical in maintaining the structure of the inhibitor binding pocket.
The flexibility of the P431G variant is compounded by the two other existing glycines
in the G-x-G-P-[VIL] motif, potentially allowing a great deal of conformational
flexibility in this region.
Pro431 is very near residues Ser429, Val432 and Asp433 (Asn532, Leu535 and Ala536
in MtuIPMS and in Figure 3.1), all of which are part of the leucine binding pocket;
with increased flexibility in the motif loop it is likely that at least some of these
residues are no longer constrained into a competent conformation for leucine binding.
The loss of a serine side chain at position 429 has already been shown above to
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decrease leucine sensitivity, but if more than one of the nearby residues are displaced
then an entire corner of the leucine binding pocket is lost. This would likely affect
leucine binding in the regulatory site.
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(a) Inhibition at 500 ￿M (S429A and T491A) or 1mM (P431G and R336A) AcCoA
and varying α-KIV concentrations — 50 and 500 ￿M
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Figure 3.10: Enzyme activity of NmeIPMS, S429A, P431G, T491A and R336A in the presence
of 1mM L-leucine. Residual activity is calculated as a percentage of full activity (in the absence
of L-leucine) for each variant.
The similarity between inhibition seen for R336A and wild-type NmeIPMS indicates
that residue Arg336 is not required for the transmission of inhibitory signal from the
leucine binding site to the active site. This is despite the fact that the interactions of
this arginine side chain at the monomer interface are clearly required for wild-type
AcCoA binding affinity.
Arg336 in NmeIPMS is equivalent to Lys434 in MtuIPMS. Interestingly, a pep-
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tide adjacent to the Lys434-interacting loop in the M. tuberculosis enzyme shows
changes in molecular dynamics upon leucine binding, as demonstrated by HDX
(Figure 3.11).49 This technique has indicated that residues 78–87 in the AcCoA
binding site incorporate fewer deuterium atoms into their backbone-amide hydro-
gens in the presence of leucine, indicating increased protection from solvent in the
presence of the allosteric inhibitor. This peptide contributes two key residues to the
active site. It is possible that the R336A substitution in NmeIPMS affects AcCoA
affinity through this peptide, in a similar mechanism to that of leucine-mediated
inhibition.
Figure 3.11: Potential mode of Lys434 influence on MtuIPMS AcCoA affinity. One monomer
of MtuIPMS structure 3FIG is shown in white, the other is coloured by domain: catalytic
domain in green, subdomain I in blue and subdomain II in pink. Zn2+ is shown in black,
α-KIV in yellow and modelled AcCoA in pink. Residues 78–87 are highlighted in black and the
key residues labelled.
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3.6 Summary of findings
NmeIPMS variants S429A, P431G, T491A and R336A were successfully cloned,
expressed and purified as for wild-type protein. These four variants were prop-
erly folded and of an appropriate size, with similar denaturation temperatures to
the wild-type protein. One further variant, G482P, was cloned and expressed, but
appears to suffer from proteolysis and was not fully characterised. This variant pos-
sesses some residual activity, but significantly reduced from the activity of wild-type
protein.
Substitution of residue Ser429 for alanine results in a variant with similar Km values
to wild-type protein and a slightly increased turnover number. This variant has
almost twice the residual activity of the wild-type protein in the presence of leucine,
indicative of the likely leucine-binding role of this serine in the NmeIPMS regulatory
domain.
Variant P431G substitutes the conserved proline for glycine in the G-x-G-P-[VIL]
motif of the leucine binding site. This variant has unchanged α-KIV affinity and
turnover number from the wild-type protein, but shows a 3-fold decrease in affinity
for the substrate AcCoA and an almost complete lack of inhibition in the presence
of leucine. Substitution of Pro431 for glycine may increase the flexibility in the
regulatory domain of the protein — such disruption of structure could then affect
the structure and dynamics of the adjacent subdomain II, and through this poten-
tially affect subdomain I and the catalytic (β/α)8-barrel. As subdomain I and the
(β/α)8-barrel form the AcCoA binding site in the protein, disruption to flexibility
in this region could represent the mechanism of change in affinity for this substrate.
Increased flexibility around Pro431 could also have more localised effects in the regu-
latory domain, by potentially displacing several leucine-binding residues from their
wild-type positions. This displacement could affect leucine binding, which would
account for the loss of leucine sensitivity. An increase in protein flexibility is con-
sistent with the decreased thermal stability observed for this variant when compared
to wild-type protein.
Similar enzyme parameters to those of variant S429A were found for variant T491A.
Thr491 is likely to stabilise leucine-binding residue Val487 in NmeIPMS, and is
highly conserved as a serine in a multiple sequence alignment of α-IPMS (Figure 3.7
and Appendix A). Substitution of this residue for alanine results in increased Km
values for both substrates, and a decreased turnover number compared to wild-type
protein. Leucine-sensitivity in this variant is similar to that observed for S429A, both
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demonstrating decreased inhibitor sensitivity compared to wild-type protein.
Lastly, interactions at the interface of the catalytic domain with subdomain II in
NmeIPMS were investigated by substitution of Arg336 for alanine. This variant
has slightly lower α-KIV affinity and turnover number than the wild-type protein,
and a 23-fold decrease in AcCoA affinity. Unlike variant P431G, in which decreased
AcCoA affinity was coupled with loss of leucine-mediated inhibition, R336A shows
similar leucine sensitivity to that of wild-type protein. It is possible that the decrease
in substrate affinity is mediated through the residues in the C-terminal loops of the
(β/α)8-barrel, several of which may interact with Arg336 and which are adjacent to
the AcCoA binding site.
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